Skip to content

A Clinical trial to study the efficacy of pH based Integrated SARS Cov-2 Immunity in Human Subjects.

PISCOV TRIAL (pH BASED INTEGRATED SARS CoV-2 )IMMUNITY IN HUMAN SUBJECTS. - PISCOV

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025490
Enrollment
110
Registered
2020-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1)Clathrin Inhibition and lethal mutagenesis of virus 2)Cholecalciferol 3)Azadirachta indica Bark extract concoction 4)Arsenicum album 5)theoxanthine, theobromine, theaflavins and polyp

Sponsors

Siddhartha Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)High risk healthy contacts of proven Covid-19 patients,2)suspect case of covid-19 for whom testing for Covid-19 could not be performed for any reason or inconclusive,3)cases with Flu like illness residing in a location reporting community transmission of Covid-19 4) cases of Interstitial pneumonia with history of close contact of Covid-19 patient and are covid-19 negative by RT-PCR 5) Healthcare workers in direct care of Covid-19 patients. All above presenting within 5 days of exposure

Exclusion criteria

Exclusion criteria: Patients suffering from: Diabetes,high Blood Pressure,Coronary Heart disease,Heart Failure,Scepticaemia,Cancer,Acute or Chronic Pulmonary disease,Chronic Kidney Disease,Major Nutritional disorder,Immunocompromised State like HIV ,post organ transplant recipient,Pregnant woman,Chronic Liver Disease,Major Neurological Disorder,Anosmia,Acute dysarthria, Acute abdomen or Gastrointestinal emergency,Major Trauma,Pyrexia of Unknown origin and any other life threatening illness which requires dedicated medical care.

Design outcomes

Primary

MeasureTime frame
Full(100%) protection from Covid-19 infection and Disease.Timepoint: 5 weeks

Secondary

MeasureTime frame
All cause hospitalisation or mortality.Timepoint: 5 weeks

Countries

India

Contacts

Public ContactMr Javed Khan

Siddhartha Hospital/ DEI Faculty of Integrated Medicine ,Dayalbagh Educational Institute,

agarwalsapna@hotmail.com9359934773

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026